Keyword
Quick search:
Content Search
Result Content Research
Result Content Research
1 Dyne (DYN) falls 0.21% in Active Trading on July 26
2 Dyne Therapeutics Inc. (NASDAQ: DYN) Fall -3.37% In Six Months, Here's What We Should Expect Now
3 Dyne Therapeutics Inc (DYN) gains 0.53% for July 16
4 Why Dyne Therapeutics Inc. (DYN) stock underperformed on Friday?
5 Dyne Therapeutics to Present at Jefferies Virtual Healthcare Conference
6 Dyne Therapeutics Reports First Quarter 2021 Financial Results and Business Highlights
7 Dyne Therapeutics Reports Fourth Quarter and Full Year 2020
8 Dyne Therapeutics Announces Chief Scientific Officer Transition
9 Dyne Therapeutics Announces Pricing of $168 Million Public Offering
10 Dyne Therapeutics Presents New Preclinical Data from its Myotonic Dystrophy Type 1 Program During American Society
11 Dyne Therapeutics Announces Pricing of Initial Public Offering
12 Dyne Therapeutics Appoints Ashish Dugar, Ph.D., MBA, Senior Vice President, Global Head of Medical Affairs
13 Dyne Therapeutics Presents Preclinical Data from its
14 Dyne Therapeutics Fills Office-Lab Building in Waltham, Massachusetts
15 Dyne Therapeutics gunning for $100M IPO weeks after a $115M raise
16 West Financial Advisors, LLC B
17 Dyne Therapeutics Myotonic Dystrophy Type 1 Program Achieves Robust RNA Knock Down of Toxic Human Nuclear
18 Dyne Therapeutics Announces $115 Million Financing to Advance Pipeline of Modern Oligonucleotide Therapeutics for Serious Muscle Diseases
19 Dyne Therapeutics to quadruple size of Waltham HQ
20 Dyne Therapeutics raises $233M in 19th Mass. IPO this year
21 Dyne Therapeutics Inc (DYN) gains 2.6690% for June 24
22 Dyne Therapeutics Launches with $50 Million Series A to Develop Targeted Therapies for Muscle Diseases
23 The Daily Biotech Pulse: Moderna Inks 2 R&D Deals, BioNTech To Buy Manufacturing Facility, Dyne Therapeutics IPO
24 Dyne Eyes IPO for R&D of Genetic Medicines for Rare Muscle Diseases
25 CureDuchenne Congratulates Dyne Therapeutics On Its Initial Public Offering
26 Here's Why We're Not Too Worried About Dyne Therapeutics' (NASDAQ:DYN) Cash Burn Situation
27 One month after $115M megaround, muscle disease-focused Dyne goes public with $233M IPO
28 Movers & Shakers, Feb. 12 | BioSpace
29 Dyne Therapeutics Inc (DYN) falls -0.4100% for June 25
30 Dyne Therapeutics Demonstrates FORCE™ Platform's Potential to Deliver Potent Exon-Skipping Molecules Directly to Muscle to Treat Duchenne Muscular Dystrophy
31 Dyne Therapeutics Appoints Susanna High as Chief Operating Officer
32 Why Editas Medicine, Inovio, Dyne, and CytomX Stocks Are Falling Today
33 Dyne Therapeutics Expands Leadership Team with Key Hires
34 Dyne Therapeutics Announces Appointment of Leading DMD Expert Francesco Muntoni to Scientific Advisory Board
35 Dyne Therapeutics Announces Appointment of Joshua Brumm as President and Chief Executive Officer
36 Dyne Therapeutics Accelerates Programs in Facioscapulohumeral Muscular Dystrophy (FSHD) with Exclusive Licensing of Technologies to Target Genetic Basis of FSHD and Expanded Scientific Advisory Board
37 Tizona completes spinout of cancer program as part of Gilead buyout; Dyne files for $100M IPO
38 The Daily Biotech Pulse: Fulgent's Big Quarter, Gilead Awaits FDA Decision, Apellis Winds Up COVID-19 Study
39 The Daily Biotech Pulse: Addex Jumps On Positive Data For Out-Licensed Drug, COVID-19 Vaccine Developer Inovio Announces $150M Follow-On Offering, Boston Scientific Goes Shopping
40 Bluebird's Susanna High Jumps to Dyne for Chief Operating Officer Role
41 Duchenne Muscular Dystrophy Pipeline Review, H2 2020: Therapeutics Assessment, Competitive Landscape, Drug Profiles, Dormant Projects
42 Other news to note for June 25, 2021 | 2021-06-25
43 The Daily Biotech Pulse: Merck Completes Organon Spin-Off, Auris Repositions As RNA Therapeutic Company With Trasir Purchase, Replimune's Readout
44 The Daily Biotech Pulse: DBV's Positive FDA Feedback, Pfizer's Cancer Drug Gets Label Expansion, Applied DNA COVID Testing Volume Surges
45 Dyne Appoints Brumm President & CEO, Subramanian Shifts to CSO
46 77 Biggest Movers From Yesterday
47 The Daily Biotech Pulse: Bristol-Myers Squibb's Skin Cancer Readout, Cellect Strikes Reverse Merger Deal, Lava Therapeutics Makes Nasdaq Debut
48 Forbion secures EUR 460 million for oversubscribed fifth fund
49 The Daily Biotech Pulse: Aptinyx Jumps On Positive Readout, Cara Executes Korsuva Licensing Deal, Cleveland BioLabs Rallies On Reverse Merger
50 IPO Outlook For The Week: Snowflake and Amwell Lead Busy 12 IPO Lineup
51 Triplet Therapeutics Announces Participation in Natural History Study of Myotonic Dystrophy Type 1
52 Edgewise Therapeutics Proposes Terms For $150 Million IPO
53 The Daily Biotech Pulse: Eton Snags Second FDA Nod For Month, Vaccine Updates from Moderna, CureVac
54 Fulcrum's Losmapimod Improves Multiple Measures, But Not Primary Endpoint
55 Cerevance Appoints David Lubner to Board of DirectorsLife sciences industry veteran brings more than 25 years of financial and operational experience
56 Bio Roundup: Seres Soars, MesoBlast Vote, Duchenne Decision & More
57 Vor Biopharma Appoints David Lubner to Its Board of Directors
58 Bio Roundup: A Telehealth Combo, FDA's BCMA OK, Biogen's Bet & More
59 How Does Closing A Deal Impact Subsequent Pitches
60 Dyne Therapetuics Highlights Presentation Of Preclinical Data From Facioscapulohumeral Musclar Dystrophy Program During FSHD Society Int'l. Research Congress
61 Hillhouse Capital Advisors, Ltd. Buys I-MAB, Playtika Holding Corp, Tuya Inc, Sells JD.
62 IPO market gears up for busiest week since May 2019 — when Uber went public — with 12 deals on tap
63 Gemini Therapeutics Appoints David Lubner as Independent Director
64 VC funding update: Boston startups and tech firms raised $1.3B in August
65 Genentech gains clinical development exec by appointing Lilli Petruzzelli; Paul Sekhri caps eventful week, naming Sapna Srivastava CFO of eGenesis
66 Forbion Announces Final Close of Forbion Growth Opportunities Fund I at EUR 360 Million (USD 428 Million)
67 Oxford expands suburban portfolio with $151M Framingham buy
68 22nd Century Group, Inc. (XXII) Stock Trending Down as Changes to Tobacco Regulation Still Pending
69 15 Firms To Steer IPOs Totaling $6.7B Amid Market Blitz
70 Biotech Roundup: FDA Culpa, Tricida Trips, Freenome's Funding & More
71 U.S. IPO Weekly Recap: The IPO Market Gears Up For Fall With Wave Of Filings In A 2 IPO Week
72 US IPO Week Ahead: The IPO market braces for a September SNOWstorm in a 14 IPO week
73 Major Logical Reasons Behind Puxin Limited (NEW), Inovio Pharmaceuticals Inc. (INO) Growth
74 FSHD Society's 28th Annual International Research Congress on facioscapulohumeral muscular dystrophy
75 On Rare Disease Day, Boston area biotechs put a spotlight on patients
76 Nasdaq Welcomes 14 IPOs in 5 Days as IPO Activity Surges This September
77 AbbVie to sell Allergan Biologics to Pharmaron for $119 million
78 Stocks To Watch: Nike, FedEx, Rising Yield Plays And A Sports ETF
79 Cambridge biotech Oncorus to test cancer drug in humans after raising $80M
80 'Rising star' CEO recounts path from pre-med to breakthrough meds; Dendreon taps Big Pharma vet Jason O'Neill as CEO
81 Wall Street Breakfast: The Week Ahead
82 CHMP nods through eight applications but nixes Flynpovi in FAP
83 Avidity Biosciences Gets $35M in Immunology R&D Deal with Eli Lilly
84 Stocks That Hit 52-Week Highs On Tuesday On Tuesday morning, 323 companies hit new 52
85 The Week Ahead In Biotech: Decision Day For Bausch Health, IPO Flow Resumes, Oncology Conference
86 With $3.5B deal, Blackstone says it's now Cambridge's largest biotech office owner
87 2020 Technology and Life Sciences IPO Report | Wilson Sonsini Goodrich & Rosati
88 Business Briefs: UH President Renu Khator Appointed to NCAA Division I Board of Directors
89 DHEC says masks working vs. COVID-19; Duke study suggests neck gaiters least effective
90 Alexion creates new post for chief diversity officer; Barry Greene stepping down at Alnylam, Yvonne Greenstreet named as successor
91 Stocks To Watch: Amazon, Apple, Zoom And Stimulus Drama
92 Stocks That Hit 52-Week Highs On Thursday
93 FREQ Stock Forecast, Price & News (Frequency Therapeutics)
94 Charles River Laboratories Adds Nancy C. Andrews, M.D., Ph.D., to Board of Directors
95 OVID Stock Forecast, Price & News (Ovid Therapeutics)
96 Cramer Weighs In On Alteryx, Uber And More
97 Here's How Much Investing $1000 In AMD At Dot-Com Bubble Peak Would Be Worth Today
98 UMRX Stock Forecast, Price & News (Cogent Biosciences)
99 Aramark Announces Exclusive Partnership with Talon
100 CBAY Stock Forecast, Price & News (CymaBay Therapeutics)